Evolus, Inc.
Evolus develops aesthetic injectable products including Jeuveau (prabotulinumtoxinA-xvfs), a neurotoxin; Evolysse, hyaluronic acid gels; and Profhilo, an injectable for skin quality.
10-QNov 16Latest SEC filing
Nov 4Latest story
Evolus develops aesthetic injectable products including Jeuveau (prabotulinumtoxinA-xvfs), a neurotoxin; Evolysse, hyaluronic acid gels; and Profhilo, an injectable for skin quality.
November 2026
August 2026
July 2026